Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560561 | 0.85 | TYR (0.35) | TYRALDH1A1ALDH1A3TSHRCYP2A6 | |
| SCHEMBL841444 | 0.85 | TYR (0.35) | TYRALDH1A1ALDH1A3TSHRCYP2A6 | |
| SCHEMBL2554581 | 0.85 | TYR (0.35) | TYRALDH1A1ALDH1A3TSHRCYP2A6 | |
| SCHEMBL15329686 | 0.82 | TYR (0.33) | TYRALDH1A1ALDH1A3TSHRCYP2A6 | |
| SCHEMBL2554013 | 0.82 | TYR (0.33) | TYRALDH1A1ALDH1A3TSHRCYP2A6 | |
| SCHEMBL15994039 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRCYP2A6FDPSKDM4E | |
| SCHEMBL27435543 | 0.78 | CNR2 (0.37) | TYRCHRNA7ALDH1A1TSHRKDM4E | |
| SCHEMBL2560556 | 0.77 | ALDH1A1 (0.35) | ALDH1A1ALDH1A3TSHRFDPS | |
| SCHEMBL15329693 | 0.77 | ALDH1A1 (0.35) | ALDH1A1ALDH1A3TSHRFDPS | |
| SCHEMBL31191175 | 0.76 | ALDH1A1 (0.32) | ALDH1A1ALDH1A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744273-B2 | Sweetness enhancing volatile compositions and methods of increasing perceived sweetness of a comestible | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-20190254322-A1 | SWEETNESS ENHANCING VOLATILE COMPOSITIONS AND METHODS OF INCREASING PERCEIVED SWEETNESS OF A COMESTIBLE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2019-08-22 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018053344-A1 | SWEETNESS ENHANCING VOLATILE COMPOSITIONS AND METHODS OF INCREASING PERCEIVED SWEETNESS OF A COMESTIBLE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-9751879-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170119034-A1 | COMPOSITIONS AND METHODS FOR MODIFYING PERCEPTION OF SWEET TASTE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-05-04 | — | — | US | disclosed |
| EP-2888245-B1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130280400-A1 | COMPOSITIONS AND METHODS FOR MODIFYING PERCEPTION OF SWEET TASTE | NATIONAL SCIENCE FOUNDATION | 2013-10-24 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| CN-1379777-A | Amino-triazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| EP-1214322-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-19 | — | — | EP | disclosed |
| US-6355653-B1 | DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS | HOFFMANN-LA ROCHE INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001017999-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | CACNA1E, CHRM1, CHRM2 | TYR 2668/4885CHRNA7 45/4885ALDH1A1 774/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | TYR 3371/4885CHRNA7 4869/4885ALDH1A1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.